Last reviewed · How we verify
Aridol Kit (MANNITOL)
Mannitol works by drawing water into the bloodstream from surrounding tissues, increasing urine production and reducing fluid accumulation in the body.
Aridol Kit (Mannitol) is a small molecule osmotic diuretic originally developed by Baxter Healthcare, which remains the current owner. It was FDA-approved in 1964 for various indications including benign intracranial hypertension, cerebral edema, and cystic fibrosis. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its potential to cause dehydration and electrolyte imbalances. Aridol Kit is used to treat conditions characterized by fluid accumulation in the body.
At a glance
| Generic name | MANNITOL |
|---|---|
| Sponsor | Baxter |
| Drug class | Osmotic Diuretic [EPC] |
| Target | sodium channels |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1964 |
Mechanism of action
The precise mechanism of action of BRONCHITOL in improving pulmonary function in cystic fibrosis patients is unknown.
Approved indications
- Benign intracranial hypertension
- Cerebral edema
- Cystic fibrosis
- Edema
- Hemolysis Prevention
- Ocular hypertension
Common side effects
- pulmonary edema
- hypertension
- tachycardia
- angina-like chest pains
- skin necrosis
- thrombophlebitis
- urinary retention
- osmotic nephrosis
- acidosis
- dehydration
- fluid and electrolyte imbalance
- convulsions
Key clinical trials
- A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects (PHASE3)
- Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study (PHASE3)
- Long Term Administration of Inhaled Mannitol in Cystic Fibrosis (PHASE3)
- Effect of Infusion Warming on Mannitol Infusion Pain in Patients With Acute Ocular Hypertension (NA)
- Dose-dependent FODMAP Reintroduction in IBS (NA)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aridol Kit CI brief — competitive landscape report
- Aridol Kit updates RSS · CI watch RSS
- Baxter portfolio CI